# INV-6452

Source: https://onco.cc/drugs/inv-6452/  
OnCo record `inv-6452` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

INV-6452 is an experimental form not stated by the company or the registry from Shenzhen Ionova Life Sciences, in phase 1 trials for HR-positive HER2-negative breast cancer, ovarian cancer and endometrial cancer.

## Summary

INV-6452 is a form not stated by the company or the registry (oral) from Shenzhen Ionova Life Sciences. Taken orally once daily in HR-positive, HER2-negative breast cancer and other solid tumours; no source found states its target or mechanism. Its furthest stage is phase 1, for HR-positive HER2-negative breast cancer, ovarian cancer and endometrial cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 first-in-human, recruiting, started 2025-07-04 (registry). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: INV-6452
- Modality: Form not stated by the company or the registry (oral)
- Mechanism: Taken orally once daily in HR-positive, HER2-negative breast cancer and other solid tumours; no source found states its target or mechanism.

## Sources

- Shenzhen Ionova Life Sciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07612891
- Shenzhen Ionova Life Sciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07612891
- ClinicalTrials.gov: trials of INV-6452: https://clinicaltrials.gov/search?intr=INV-6452

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/)
- trials: [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor](https://onco.cc/trials/nct07612891/)

---
JSON: https://onco.cc/api/v1/entities/inv-6452.json